secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001823239-23-000077
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai LifeSciences completes planned CEO succession; Martin becomes CEO, Hull Executive Chairman
--------------------------------------------------------------------------------

- William 'Trey' Martin, III named CEO effective July 27, 2023; previously President of Biologics Safety Testing segment.
- Carl Hull transitions from interim CEO to Executive Chairman; annual base salary reduced to $500,000.
- Hull's target annual bonus set at 100% of salary for 2024+; 2023 target remains $757,667.
- Martin's compensation unchanged from his prior role as President of Biologics Safety Testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/0001823239-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000077/mrvi-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001823239-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer